Teva's Biosimilar Boom Just Beginnings: Is It Time to Buy?
Teva is turning the corner with a growing biosimilars roster and improving margins. This article examines whether tev...
Focusing on short term investment goals can yield quick financial returns. Discover the right timing for your investment strategy.
27,474 articlesTeva is turning the corner with a growing biosimilars roster and improving margins. This article examines whether tev...
New York’s one-year moratorium on hyperscale data centers upends AI infrastructure planning and tests how governments...
Over five years, SPDR’s XLK delivered a 35-point edge on the S&P 500, even as a Feb 2026 pullback tested investor ner...
The White House extended the deadline for Iran to reopen the Strait of Hormuz to April 6, sparking a fresh wave of oi...
SpaceX has sprinted out of the gate after its IPO, up roughly 49% from the offer price. As December approaches, inves...
AI demand is driving a surge in data-center energy use, and space won’t be a quick fix. This report explains why runn...
Broadcom reported a strong Q1 FY2026 with AI-driven growth and a deep backlog, setting up a targeted, three-year broa...
A leading defense analyst warns of a readiness gap as U.S. munitions deliveries lag demand, signaling a multiyear bud...
Could Netflix stock fall? This guide delves into the bear case, valuation pressures, and practical steps investors ca...
A drone strike lit a cargo ship off Qatar, testing a fragile Iran ceasefire. UAE and Kuwait reported drone incursions...
A fast-tracked Nasdaq-100 adds a new catalyst for space stocks. Rocket Lab is poised to enter the index ahead of Spac...
AI fears roiled tech names, dragging CrowdStrike lower despite strong fundamentals. Analysts see a 40% upside as sent...